Measurement of granulocyte CD16b provides a reliable and rapid screening method for IGD that complements genetic testing. Implementation of this assay by a commercial provider, together with validated cutoffs, enables nationwide, insurance-covered diagnostic testing and functional confirmation of GPI pathway gene variants, representing a significant advance in IGD diagnosis.
Tanigawa et al. (Sat,) studied this question.